Allen & Hanburys Ltd

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Summary of Product Characteristics last updated on the eMC: 20/08/2009
SPC Serevent Diskhaler

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 20/08/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Updated on 15/07/2008 and displayed until 20/08/2009
Reasons for adding or updating:
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 19/10/2007 and displayed until 15/07/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Updated on 18/03/2004 and displayed until 19/10/2007
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic Indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
Updated on 06/11/2003 and displayed until 18/03/2004
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 4.3 - Contra-indications
  • Change to section 6.1 - List of Excipients
Updated on 29/09/2003 and displayed until 06/11/2003
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 4.3 - Contra-indications
  • Change to section 6.1 - List of Excipients
Updated on 17/08/2001 and displayed until 29/09/2003
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 09/04/2001 and displayed until 17/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 22/03/2001 and displayed until 09/04/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 21/09/2000 and displayed until 22/03/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 21/09/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   salmeterol xinafoate